Indacaterol是一种口服有效的超长效β2肾上腺素受体激动剂，通过β-arrestin2依赖性方式抑制NF-κB活性，减轻肺部损伤并改善慢性阻塞性肺病肺功能，同时具有心血管疾病研究潜力。
| 英文别名 (English Synonym) | Indacaterol |
| 中文名称 (Chinese Name) | 茚达特罗 |
| 靶点 (Target) | Adrenergic Receptor |
| 通路 (Pathway) | GPCR/G protein |
| CAS号 (CAS NO.) | 312753-06-3 |
| 分子式 (Formula) | C24H28N2O3 |
| 分子量 (Molecular Weight) | 392.49 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Lee SU, Ahn KS, Sung MH, Park JW, Ryu HW, Lee HJ, Hong ST, Oh SR. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37(8):585-91. doi: 10.14348/molcells.2014.0076. Epub 2014 Aug 18. PMID: 25134539; PMCID: PMC4145369.
[2] Ye Y, Gong H, Wang X, Wu J, Wang S, Yuan J, Yin P, Jiang G, Li Y, Ding Z, Zhang W, Zhou J, Ge J, Zou Y. Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice. J Cardiovasc Pharmacol. 2015 Jun;65(6):628-39. doi: 10.1097/FJC.0000000000000230. PMID: 25806688; PMCID: PMC4461387.
